[go: up one dir, main page]

Abdella et al., 2004 - Google Patents

POSTERS: COMPLICATIONS-NEPHROPATHY

Abdella et al., 2004

Document ID
6174961126178470693
Author
Abdella N
Mojiminiyi O
Al Dahi W
Bellin C
et al.
Publication year
Publication venue
Diabetes

External Links

Snippet

Background: Diabetes is the most common cause of end-stage renal disease in Kuwait. We postulate that inappropriately low erythropoietin (Epo) concentration occurs early in the development of nephropathy even in patients without anemia. This study investigates the …
Continue reading at search.proquest.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Similar Documents

Publication Publication Date Title
Sharma et al. Adiponectin regulates albuminuria and podocyte function in mice
Sabbagh et al. Repression of osteocyte Wnt/β‐catenin signaling is an early event in the progression of renal osteodystrophy
Király et al. Swim training prevents hyperglycemia in ZDF rats: mechanisms involved in the partial maintenance of β-cell function
Wolf et al. p27Kip1 knockout mice are protected from diabetic nephropathy: evidence for p27Kip1 haplotype insufficiency
US10576148B2 (en) Use of VAP-1 inhibitors for treating fibrotic conditions
US9726659B2 (en) CMPF as a biomarker for diabetes and associated methods
US20100190686A1 (en) Novel secreted proteins of adipocytes for diagnostic purposes
JP2007516708A (en) RBP4 in insulin sensitivity / resistance, diabetes and obesity
Hällgren et al. Serum levels of human pancreatic polypeptide in renal disease
Dullaart et al. Alterations in serum lipids and apolipoproteins in male type 1 (insulin-dependent) diabetic patients with microalbuminuria
Lopes et al. Effects of cyclosporine and sirolimus on insulin-stimulated glucose transport and glucose tolerance in a rat model
Kumari et al. Deletion of insulin receptor in the proximal tubule and fasting augment albumin excretion
Cohen et al. Inhibiting albumin glycation attenuates dysregulation of VEGFR-1 and collagen IV subchain production and the development of renal insufficiency
Sato et al. Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model
Hommel et al. On the pathogenesis of arterial blood pressure elevation early in the course of diabetic nephropathy
Satoh et al. Elevated plasma immunoreactive neuropeptide Y concentrations and its increased urinary excretion in patients with advanced diabetic nephropathy
JP2016508509A (en) Modified INGAP peptide for treating diabetes
Cobbs et al. Saturated fatty acids bound to albumin enhance osteopontin expression and cleavage in renal proximal tubular cells
Abdella et al. POSTERS: COMPLICATIONS-NEPHROPATHY
Panuccio et al. Low parathyroid hormone and pentosidine in hemodialysis patients
Deyneli et al. Effects of ACE inhibition and angiotensin II receptor blockade on glomerular basement membrane protein excretion and charge selectivity in type 2 diabetic patients
De Koning et al. High prevalence of pancreatic islet amyloid in patients with end‐stage renal failure on dialysis treatment
US20160000866A1 (en) Cthrc1 receptor and methods of use thereof
Takahashi et al. Association between serum adiponectin levels and arteriolosclerosis in IgA nephropathy patients
WO2006010533B1 (en) Pancreatic polypeptide as target/marker of beta cell failure